Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma

Key facts

Sponsor

Shanghai Henlius Biotech

Intervention

HLX13(drug)

Enrollment

246 enrolled

Eligibility

18-65 years · All sexes

Timeline

2025 – 2026

Study locations (30)

• Oncology Physicians Network (OPN) - Los Alamitos /OPN Healthcare, Glendale, California, United States
• Los Angeles Cancer Network, Glendale, California, United States
• Cancer Specialists of North Florida, Jacksonville, Florida, United States
• D&H National Research Centers, LLC, Margate, Florida, United States
• Mid Florida Hematology and oncology Center, Orange City, Florida, United States
• Florida Clinical Trials Group, Plantation, Florida, United States
• Florida Clinical Trials Group, Tamarac, Florida, United States
• HCA Research Institute, LLC, Brentwood, Tennessee, United States
• Oncology Consultants, Houston, Texas, United States
• American Oncology Network Vista Oncology Division/Physician Partner Associate, Olympia, Washington, United States
• Northwest Medical Specialties PLLC (NWMS), Tacoma, Washington, United States
• Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
• Peking Union Medical College Hospital, Beijing, China
• Peking university international hospital, Beijing, China
• The First Affiliated Hospital of Bengbu Medical University, Bengbu, China
• +15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Adult hepatocellular carcinoma

Additional recruiting or active studies for the same condition.

• ENROLLING BY INVITATIONPHASE2NCT07441369
  Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer
  Fudan University
• RECRUITINGPHASE2NCT07175441
  Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma
  Riboscience, LLC.
• RECRUITINGPHASE2NCT07560488
  Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma
  Tianjin Medical University Cancer Institute and Hospital
• RECRUITINGPHASE1, PHASE2NCT07291076
  A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
  Bristol-Myers Squibb
• RECRUITINGPHASE2NCT07010497
  A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular Carcinoma
  Asan Medical Center
• RECRUITINGPHASE1, PHASE2NCT07500220
  Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC
  Beijing Biotech
• RECRUITINGPHASE2NCT07413354
  Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma
  Tongji Hospital
• RECRUITINGNANCT07365527
  Sonoporation and Tumor Microenvironment Response in Colorectal Liver Metastases
  Zealand University Hospital

See all trials for Adult hepatocellular carcinoma →